Search

everythinglearnresearchcommunity

for

Search:↓

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

Tirzepatide may improve hair loss by reducing insulin resistance.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

A woman with a rare ovarian tumor and hyperparathyroidism improved after surgery, highlighting the need for reporting unusual cases to understand and manage rare diseases.

Compounds from Eclipta prostrata L. plant have diabetes and obesity-fighting properties and reduce inflammation.

Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.

Thyroid receptor β can help develop new drugs to treat hair loss.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

PAR-1 may play a role in hair growth regulation in human hair follicles.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Targeting the PGD2-DP2 pathway may help treat hair loss.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.